|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
No reversal candles currently present.
PROFILE: Opthea (OPT.AX)
Stock Exchange: ASX
Ticker Codes: | OPT.AX | ASX:OPT |
Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.
|AJX Alexium International||0.06||14||224,969||0||NEUTRAL|
|MNS Milnes Holdings||0.08||7.1||959,142||0||NEUTRAL|
|ABC Adelaide Brighton||3.06||6.3||4,642,840||0||NEUTRAL|
|APE Ap Eagers Holdings||9.01||6.1||633,117||0||NEUTRAL|
|CDV Cardinal Resources||0.37||5.7||1,772,012||0||NEUTRAL|
|RFG Retail Food||0.1||5.4||3,641,364||0||NEUTRAL|
|FDV Frontier Digital Ventures||1||5.3||159,343||0||NEUTRAL|